Crescent Biopharma, Inc. (CBIO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Crescent Biopharma, Inc. (CBIO) trades at $17.15 with AI Score 21/100 (Grade F). Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates. Market cap: $637M, Sector: Healthcare.
Price as of Aug 22, 2026 · Last analyzed: May 9, 2026CBIO stock analysis for 2026: Analysts have set a consensus price target of $33.00 for Crescent Biopharma, Inc., suggesting 92.4% upside from the current price of $17.15. The AI MoonshotScore is 21/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
CBIO: 3/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Crescent Biopharma, Inc. (CBIO) Healthcare & Pipeline Overview
Crescent Biopharma, Inc. is a biotechnology firm specializing in cancer therapy research and development, focusing on novel bispecific antibodies like CR-001, CR-002, and CR-003. The company's strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical enhances its capabilities in developing and commercializing oncology therapeutics, positioning it within the competitive biotechnology sector.
What Is the Investment Thesis for CBIO?
Crescent Biopharma, Inc. presents a focused investment opportunity within the biotechnology sector, primarily driven by its pipeline of cancer therapy candidates, including the lead asset CR-001. The strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. provides a collaborative framework for development and commercialization, potentially accelerating the path to market. Key value drivers include successful clinical trial outcomes for CR-001 and subsequent regulatory approvals. However, the company's negative profit margin of -1363.9% indicates substantial ongoing research and development expenses, posing a financial risk. Investors should closely monitor clinical trial progress, partnership milestones, and cash burn rate to assess the company's long-term viability and potential for return on investment. The company's market capitalization stands at $0.60 billion as of May 9, 2026.
Based on FMP financials and quantitative analysis
CBIO Key Highlights
Crescent Biopharma's pipeline includes CR-001, an anti-PD-1/anti-VEGF bispecific antibody targeting solid tumors, representing a potential breakthrough in cancer therapy.
- The company maintains a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., enhancing its development and commercialization capabilities in oncology.
- Crescent Biopharma's gross margin is 100.0%, indicating efficient management of direct costs associated with its research and development activities.
- The company's market capitalization is $0.60 billion, reflecting investor valuation of its current and future potential.
- Crescent Biopharma employs 41 individuals, indicating a focused and agile operational structure.
Who Are CBIO's Competitors?
CBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDXG MiMedx Group, Inc. | $4.33 | +0.70% | $631M | 90 |
| CRMD CorMedix Inc. | $8.20 | -0.36% | $643M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $11.87 | -0.17% | $702M | 93 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $16.28 | +0.00% | $816M | 73 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.89 | +1.41% | $849M | 92 |
| QTTB Q32 Bio Inc. | $15.97 | +0.69% | $475M | 83 |
| TBPH Theravance Biopharma, Inc. | $17.01 | +0.35% | $882M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBIO's Key Strengths?
Innovative bispecific antibody technology.
- Strategic partnership with Sichuan Kelun-Biotech.
- Focused pipeline of cancer therapy candidates.
- Experienced management team.
What Are CBIO's Weaknesses?
High research and development costs.
- Dependence on strategic partnerships.
- Limited commercialization experience.
- Negative profit margin.
What Could Drive CBIO Stock Higher?
Clinical trial results for CR-001 in solid tumors.
- Potential expansion of strategic partnership with Sichuan Kelun-Biotech.
- Regulatory submissions for CR-001.
- Advancement of CR-002 and CR-003 through preclinical and clinical development.
What Are the Key Risks for CBIO?
Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for CR-001.
- Regulatory delays or rejection of CR-001.
- Competition from established pharmaceutical companies.
- High research and development costs.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for CBIO?
- Successful Clinical Trials for CR-001: The successful completion of clinical trials for CR-001, Crescent Biopharma's lead anti-PD-1/anti-VEGF bispecific antibody, represents a significant growth opportunity. Positive trial outcomes could lead to regulatory approval and commercialization, potentially capturing a substantial share of the solid tumor treatment market, estimated to reach $200 billion by 2030. This growth is contingent on demonstrating superior efficacy and safety compared to existing therapies, providing a competitive advantage.
- Expansion of Strategic Partnerships: Expanding strategic partnerships with other biotechnology and pharmaceutical companies can provide Crescent Biopharma with access to additional resources, technologies, and market channels. These collaborations can accelerate the development and commercialization of its pipeline assets, reducing risk and increasing the potential for revenue generation. The market for pharmaceutical collaborations is projected to grow to $150 billion by 2028, offering ample opportunities for Crescent Biopharma to forge mutually beneficial alliances.
- Advancement of CR-002 and CR-003: Advancing the development of CR-002 and CR-003, the other assets in Crescent Biopharma's pipeline, represents another key growth opportunity. Successful preclinical and clinical development of these candidates could expand the company's product portfolio and address additional unmet needs in cancer treatment. Each successful drug approval can unlock significant market potential, with peak sales often reaching hundreds of millions or even billions of dollars.
- Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, can drive revenue growth for Crescent Biopharma. These regions offer large patient populations and increasing healthcare spending, creating significant opportunities for commercializing its cancer therapies. The global oncology market is expected to grow rapidly in these regions, driven by rising cancer incidence and improved access to healthcare.
- Combination Therapies: Exploring and developing combination therapies involving CR-001 and other agents represents a promising growth avenue. Combining bispecific antibodies with other immunotherapies or targeted agents can enhance efficacy and overcome resistance mechanisms in cancer treatment. The market for combination therapies is growing rapidly, driven by the increasing recognition of the benefits of personalized and multi-faceted treatment approaches.
What Are CBIO's Competitive Advantages?
- Proprietary bispecific antibody technology platform.
- Strategic partnership with Sichuan Kelun-Biotech provides access to resources and expertise.
- Focus on innovative cancer therapies addresses a significant unmet need.
What Does CBIO Do?
Crescent Biopharma, Inc. is a biotechnology company dedicated to the research and development of innovative cancer therapy candidates. The company's pipeline features several promising assets, including CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody designed to target solid tumors. Additionally, Crescent Biopharma is developing CR-002 and CR-003 as part of its broader oncology portfolio. Crescent Biopharma has established a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., aimed at the collaborative development and commercialization of oncology therapeutics, including novel combinations. This partnership enhances Crescent Biopharma's capabilities and expands its reach in the oncology market. Headquartered in Waltham, Massachusetts, Crescent Biopharma operates with a focused team of 41 employees, driving its research and development efforts. The company's commitment to innovation and strategic collaborations positions it as a player in the competitive biotechnology landscape, striving to address unmet needs in cancer treatment. Crescent Biopharma's approach combines internal research with external partnerships to accelerate the development and delivery of novel cancer therapies.
What Products and Services Does CBIO Offer?
- Researches and develops cancer therapy candidates.
- Develops proprietary anti-PD-1/anti-VEGF bispecific antibodies to treat solid tumors.
- Focuses on oncology therapeutics, including novel combinations.
- Partners with Sichuan Kelun-Biotech Biopharmaceutical for development and commercialization.
- Aims to address unmet needs in cancer treatment through innovative therapies.
How Does CBIO Make Money?
- Develops and patents novel cancer therapy candidates.
- Out-licenses or co-develops its drug candidates with strategic partners like Sichuan Kelun-Biotech.
- Generates revenue through milestone payments, royalties, and potential future product sales.
What Industry Does CBIO Operate In?
Crescent Biopharma operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The oncology therapeutics market is a major segment within biotechnology, driven by the increasing prevalence of cancer and the demand for innovative treatments. Crescent Biopharma's focus on bispecific antibodies and strategic partnerships aligns with industry trends toward targeted therapies and collaborative drug development. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in this rapidly evolving field.
Who Are CBIO's Key Customers?
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients with solid tumors who may benefit from novel bispecific antibody therapies.
- Healthcare providers who prescribe and administer cancer treatments.
Crescent Biopharma, Inc. Financial Trajectory
Crescent Biopharma, Inc. (CBIO) reported $1.0M in revenue for Q1 2026, a decline of 90.4% compared to the prior quarter. The company recorded a net loss of $23.3M, with diluted EPS of $-0.77.
Company Profile
Crescent Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Joshua T. Brumm. CBIO has traded publicly since 2014.
How Crescent Biopharma, Inc. Is Valued
Crescent Biopharma, Inc. carries a market capitalization of $637M, placing it in the small-cap category. Relative to its peer group, CBIO's quantitative score of 21/100 is below the peer average of 84/100.
Key Financial Metrics
Return on assets is -81.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -30.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Crescent Biopharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 15.03 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Crescent Biopharma, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 19.7% below estimates on average.
Forward Outlook
Wall Street analysts project Crescent Biopharma, Inc. revenue of about $1.9M for fiscal 2026, with EPS near $-2.71. The estimate reflects 6 contributing analysts.
CBIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative bispecific antibody technology.
- Strategic partnership with Sichuan Kelun-Biotech.
- Focused pipeline of cancer therapy candidates.
- Experienced management team.
Bear Case
- High research and development costs.
- Dependence on strategic partnerships.
- Limited commercialization experience.
- Negative profit margin.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1M | -$23M | -$0.77 |
| Q4 2025 | $11M | -$92M | -$4.58 |
Based on FMP financials and quantitative analysis
CBIO Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Jan 31, 2022
CBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBIO.
Price Targets
Consensus target: $33.00
CBIO MoonshotScore
What does this score mean?
The MoonshotScore rates CBIO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Crescent Biopharma, Inc. Analysis
Leadership: Joshua T. Brumm
CEO
Joshua T. Brumm serves as the CEO of Crescent Biopharma, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. Before joining Crescent Biopharma, Brumm held leadership positions at several biotech companies, focusing on corporate strategy, business development, and financial management. He has a proven track record of driving growth and innovation in the healthcare sector. Brumm's expertise spans various therapeutic areas, including oncology, immunology, and infectious diseases. His educational background includes advanced degrees in business and science, providing a strong foundation for his leadership role.
Track Record: Under Joshua T. Brumm's leadership, Crescent Biopharma has focused on advancing its pipeline of cancer therapy candidates, including CR-001. He has overseen the strategic partnership with Sichuan Kelun-Biotech, enhancing the company's development and commercialization capabilities. Brumm has also been instrumental in securing funding and resources to support the company's research and development efforts. His strategic decisions have positioned Crescent Biopharma as a player in the competitive biotechnology landscape.
Crescent Biopharma, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for CBIO?
CBIO holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates. Their pipeline includes bispecific antibodies and strategic partnerships …
What does Crescent Biopharma, Inc. do?
Crescent Biopharma, Inc. is a biotechnology company focused on the research and development of innovative cancer therapy candidates. Its primary focus is on developing bispecific antibodies, such as CR-001, which targets both PD-1 and VEGF to treat solid tumors. The company operates through strategic partnerships, most notably with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., to enhance its development and commercialization efforts.
What do analysts say about CBIO stock?
Analyst coverage of Crescent Biopharma, Inc. (CBIO) is currently limited, reflecting its stage as a development-focused biotechnology company. Key valuation metrics are influenced by the potential success of its drug pipeline, particularly CR-001. Growth considerations center on the advancement of its clinical trials and the potential for regulatory approvals.
What are the main risks for CBIO?
Crescent Biopharma, Inc. faces several key risks inherent to the biotechnology industry. A primary risk is the potential for unfavorable clinical trial results, particularly for its lead candidate CR-001, which could significantly impact its valuation and future prospects. Regulatory delays or rejection of its drug candidates also pose a substantial risk, as the approval process is complex and uncertain.
What are the key factors to evaluate for CBIO?
Crescent Biopharma, Inc. (CBIO) holds an AI score of 21/100 (low). presents a focused investment opportunity within the biotechnology sector, primarily driven by its pipeline of cancer therapy candidates, including the lead asset CR-001. Not financial advice.
How frequently does CBIO data refresh on this page?
CBIO's price was last updated on Aug 22, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CBIO's recent stock price performance?
Crescent Biopharma, Inc. (CBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative bispecific antibody technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBIO overvalued or undervalued right now?
Crescent Biopharma, Inc. (CBIO) is loss-making, so its trailing P/E is negative (-6.0x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CBIO before investing?
Before investing in Crescent Biopharma, Inc. (CBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage impacts the depth of available information.
- Financial data is based on the most recent available filings.
- Future success is dependent on clinical trial outcomes and regulatory approvals.